Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Auteurs

Grégoire Marret, Nicolas Isambert, Keyvan Rezai, Jocelyn Gal, Esma Saada-Bouzid, Frédéric Rolland, Maggy Chausson, Edith Borcoman, Marie Alt, Jerzy Klijanienko, Damien Vansteene, Joël Guigay, Maud Kamal, Ivan Bièche, Christophe Le Tourneau,